Cell & Gene Therapy Manufacturing Services Market worth $48.45 billion by 2030, growing at a CAGR of 15.81% - Exclusive Report by 360iResearch

The "Cell & Gene Therapy Manufacturing Services Market by Type (Cell Therapy, Gene Therapy), Indication (Cardiovascular Diseases, Central Nervous System Disorders, Infectious Diseases), Application, End-User - Global Forecast 2024-2030" report has been added to 360iResearch.com's offering.

The Global Cell & Gene Therapy Manufacturing Services Market to grow from USD 17.34 billion in 2023 to USD 48.45 billion by 2030, at a CAGR of 15.81%.

Request a Free Sample Report @ https://www.360iresearch.com/library/intelligence/cell-gene-therapy-manufacturing-services?utm_source=openpr&utm_medium=referral&utm_campaign=sample

Cell and gene therapy manufacturing services encompass the specialized production processes required for the development and commercialization of cell and gene therapies. The scope of these services includes a comprehensive array of production activities such as the sourcing of raw materials, cell processing, gene transfection or vector integration, culturing, harvesting, purification, quality control, and final product formulation. As cell and gene therapies are widely considered a critical component in modern therapeutic development, the importance of robust, compliant, and scalable manufacturing capabilities becomes critical. The cell and gene therapy manufacturing services market is rapidly expanding, with the increasing prevalence of genetic disorders and cancers, advances in molecular biology, and significant investments from both the public and private healthcare sectors. Collaboration between academic institutions, biotech firms, and service providers further propels the market growth. Despite the growth, the market faces several challenges, including high costs of production, stringent and evolving regulatory requirements, and the complexity of manufacturing processes. The necessity for specialized facilities and skilled personnel increases operational challenges, and ensuring consistent quality and scalability remains a significant hurdle. However, the market is ripe with opportunities, particularly in the development of automation and closed-system manufacturing to improve efficiency and reduce contamination risks. Breakthroughs in cell and gene therapy are promising for personalized medicine, thus creating lucrative opportunities for specialized cell and gene therapy manufacturing services.

In the Americas, the market for cell and gene therapy manufacturing services is experiencing robust growth. This upsurge is primarily driven by a well-established biotech ecosystem, substantial investments in research and development, and a favorable regulatory environment. Moreover, the presence of established market players and the high adoption rate of advanced therapies are catalyzing the market in America. The EMEA region is witnessing a significant expansion in the cell and gene therapy manufacturing service market, with Europe being at the forefront. The growth in the European Union is supported by strong governmental support, advanced healthcare infrastructure, and increasing collaborations between academic and industrial sectors. The Middle East and Africa are also showing growth potential, with increasing investment in healthcare infrastructure and a growing interest in advanced therapeutic modalities. The Asia-Pacific region is a rapidly emerging market in cell and gene therapy manufacturing services, driven by growing healthcare expenditures and a rising number of local companies entering the space. Technological advancements and increasing partnerships with Western companies are further propelling the market forward in this region.

Market Segmentation & Coverage:

This research report categorizes the Cell & Gene Therapy Manufacturing Services Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Type, market is studied across Cell Therapy and Gene Therapy. The Cell Therapy is further studied across Allogeneic, Autologous, and Viral Vector. The Allogeneic is further studied across Allogeneic Hematopoietic Stem Cells, Allogeneic Induced Pluripotent Stem Cells, Allogeneic Mesenchymal Stem Cells, Allogeneic Natural Killer Cells, and Allogeneic T-cells. The Autologous is further studied across Autologous Hematopoietic Stem Cells, Autologous Mesenchymal Stem Cells, Autologous Natural Killer Cells, and Autologous T-cells. The Viral Vector is further studied across Adeno-associated Virus Vectors and Retroviral Vectors. The Gene Therapy is further studied across Non-viral Vector and Oligonucleotides. The Cell Therapy commanded largest market share of 66.54% in 2023, followed by Gene Therapy.

Based on Indication, market is studied across Cardiovascular Diseases, Central Nervous System Disorders, Infectious Diseases, Oncology Diseases, Ophthalmology Diseases, and Orthopedic Diseases. The Oncology Diseases commanded largest market share of 22.31% in 2023, followed by Cardiovascular Diseases.

Based on Application, market is studied across Clinical Manufacturing and Commercial Manufacturing. The Clinical Manufacturing commanded largest market share of 72.01% in 2023, followed by Commercial Manufacturing.

Based on End-User, market is studied across Academic & Research Institutes and Pharmaceutical & Biotechnology Companies. The Pharmaceutical & Biotechnology Companies commanded largest market share of 82.16% in 2023, followed by Academic & Research Institutes.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.63% in 2023, followed by Europe, Middle East & Africa.

Inquire Before Buying @ https://www.360iresearch.com/library/intelligence/cell-gene-therapy-manufacturing-services?utm_source=openpr&utm_medium=referral&utm_campaign=inquire

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Cell & Gene Therapy Manufacturing Services Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in the Cell & Gene Therapy Manufacturing Services Market. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

Key Company Profiles:

The report delves into recent significant developments in the Cell & Gene Therapy Manufacturing Services Market, highlighting leading vendors and their innovative profiles. These include Advanced BioScience Laboratories, Inc., AGC Biologics, Bio-Techne Corporation, Bluebird Bio, Inc., Boehringer Ingelheim International GmbH, c-LEcta GmbH, Catalent, Inc., Cell and Gene Therapy Catapult, Cell Therapies Pty Ltd., Cell-Easy SAS, Charles River Laboratories International, Inc., Exmoor Pharma Concepts Limited, F. Hoffmann-La Roche Ltd., FUJIFILM Diosynth Biotechnologies, General Electric Company, Lonza Group, Merck KGaA, Miltenyi Biotec B.V. & Co. KG, Minaris Regenerative Medicine GmbH, Nikon Corporation, Novartis AG, Oxford Biomedica PLC, Recipharm AB, Resonac Corporation, Samsung Biologics Co., Ltd, Takara Holdings Inc., Thermo Fisher Scientific, Inc., uBriGene Biosciences Inc., and Wuxi Apptec Co., Ltd..

Key Topics Covered:

1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
6. Cell & Gene Therapy Manufacturing Services Market, by Type
7. Cell & Gene Therapy Manufacturing Services Market, by Indication
8. Cell & Gene Therapy Manufacturing Services Market, by Application
9. Cell & Gene Therapy Manufacturing Services Market, by End-User
10. Americas Cell & Gene Therapy Manufacturing Services Market
11. Asia-Pacific Cell & Gene Therapy Manufacturing Services Market
12. Europe, Middle East & Africa Cell & Gene Therapy Manufacturing Services Market
13. Competitive Landscape
14. Competitive Portfolio

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Cell & Gene Therapy Manufacturing Services Market?
2. Which are the products/segments/applications/areas to invest in over the forecast period in the Cell & Gene Therapy Manufacturing Services Market?
3. What is the competitive strategic window for opportunities in the Cell & Gene Therapy Manufacturing Services Market?
4. What are the technology trends and regulatory frameworks in the Cell & Gene Therapy Manufacturing Services Market?
5. What is the market share of the leading vendors in the Cell & Gene Therapy Manufacturing Services Market?
6. What modes and strategic moves are considered suitable for entering the Cell & Gene Therapy Manufacturing Services Market?

Read More @ https://www.360iresearch.com/library/intelligence/cell-gene-therapy-manufacturing-services?utm_source=openpr&utm_medium=referral&utm_campaign=analyst

Contact 360iResearch

Mr. Ketan Rohom
Sales & Marketing,
Office No. 519, Nyati Empress,
Opposite Phoenix Market City,
Vimannagar, Pune, Maharashtra,
India - 411014.
sales@360iresearch.com
+1-530-264-8485
+91-922-607-7550

About 360iResearch

360iResearch is a market research and business consulting company headquartered in India, with clients and focus markets spanning the globe.

We are a dynamic, nimble company that believes in carving ambitious, purposeful goals and achieving them with the backing of our greatest asset - our people.

Quick on our feet, we have our ear to the ground when it comes to market intelligence and volatility. Our market intelligence is diligent, real-time and tailored to your needs, and arms you with all the insight that empowers strategic decision-making.

Our clientele encompasses about 80% of the Fortune Global 500, and leading consulting and research companies and academic institutions that rely on our expertise in compiling data in niche markets. Our meta-insights are intelligent, impactful and infinite, and translate into actionable data that support your quest for enhanced profitability, tapping into niche markets, and exploring new revenue opportunities.

This release was published on openPR.